Binge Eating Disorder (BED)

Also known as: Binge eating disorder / Binge Eating Disorders / Binge-Eating Disorder

DrugDrug NameDrug Description
DB01255LisdexamfetamineAlso known as _Vyvanse_, lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine [A40246]. It is paired with the essential amino acid _L-lysine_. Lisdexamfetamine dimesylate increases attention span and decreases restlessness in children and adults who are overactive/hyperactive, cannot concentrate for long periods, or are easily distracted or impulsive [A2230]. As a central nervous system stimulant, lisdexamfetamine is utilized as an adjunct therapy in the treatment of attention deficit hyperactivity disorder (ADHD). As a prodrug, lisdexamfetamine was specifically engineered as an abuse-resistant product [F2368]. The mechanism by which this occurs is through delayed release after ingestion (unlike some other psychostimulant drugs, which may be abused). After oral administration and absorption, enzyme hydrolysis after contact with red blood cells metabolize lisdexamfetamine into L- lysine, a naturally occurring essential amino acid and active _d-amphetamine_, which is responsible for the drug’s pharmacological effects. Gastrointestinal pH does not affect this conversion, and the addition of the L-lysine slows the amount of d-amphetamine available in the circulation and central nervous system [F2368].
DB01104SertralineSertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake [T28]. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects [A1844]. Sertraline displays a better safety or tolerability profile than other classes of antidepressants [A1846]. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants or monoamine oxidase inhibitors [T28]. Sertraline has shown therapeutic effectiveness as a treatment for major depressive disorder [A1836], obsessive-compulsive disorder (OCD) [A1838], panic disorder, post-traumatic stress disorder (PTSD) [A1841], premenstrual dysphoric disorder (PMDD) [A1842] and social anxiety disorder (social phobia).
DB00273TopiramateTopiramate (brand name Topamax) is an anticonvulsant drug produced by Ortho-McNeil Neurologics, a division of Johnson & Johnson. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines. [Wikipedia]. A combination product containing phentermine and topiramate extended-release called QSYMIA® is indicated for the management of obesity. On August 2013, an extended released formulation, marketed as Trokendi XR has been approved for the management of partial onset, tonic-clonic, and Lennox-Gastaut Syndrome seizures.
DrugDrug NamePhaseStatusCount
DB00659Acamprosate2 / 3Completed1
DB01156Bupropion2 / 3Completed1
DB01156Bupropion2 / 3Enrolling by Invitation2
DB01156Bupropion2 / 3Recruiting1
DB12305Dasotraline2 / 3Completed1
DB01183Naloxone2 / 3Unknown Status1
DB00704Naltrexone2 / 3Enrolling by Invitation2
DB00704Naltrexone2 / 3Recruiting1
DB09072Sodium oxybate2 / 3Completed1
DB00273Topiramate2 / 3Completed1
DB12305Dasotraline3Active Not Recruiting1
DB00704NaltrexoneNot AvailableCompleted1